Prospector
Profile
07.1513
|
| |
| Molecular Pharmacology (USA) Limited |
NAICS |
541710 |
| 8721 Santa Monica Boulevard, Suite 1023
Los Angeles, CA 90069 |
Description |
Biotechnology |
| (310) 694-8976 |
Employees |
1 |
| http://www.mpl-usa.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-0.3770 |
| |
Assets |
(mil) |
0.0470 |
| |
Liability |
(mil) |
1.3590 |
| |
(for the year ended 2007-06-30) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
James Stafford Chartered Accountants raised doubts on the ability of Molecular Pharmacology (USA) Limited to continue as a going concern after auditing its financial statements. The Company has a loss of $377,131 for the eight month period ended June 30, 2007 and has a working capital deficiency of $23,913 at June 30, 2007.
|
| |
|
Intellectual Property:
To protect their intellectual property rights, the Company relies on a combination of license and patent applications held by Cambridge Scientific Pty Ltd., namely "Analgesic and Anti-Inflammatory Composition" comprising USA patent application in completion plus PCT Provisional Specification having the same name designated as Serial No. 11/059580. These patent applications embody all the current Analgesic and Anti-inflammatory assets. The Company also relies on the exclusive nature of license, trademark and copyright law, trade secret protection, confidentiality agreements and other contractual arrangements, as it may execute from time to time. [SEC Filing 10-KSB 10-12-07]
|
| |
|
Description:
The Company engages in the development and commercialization of analgesic and anti-inflammatory molecule, known as Tripeptofen.
|
| |
|
Officers:
Jeffrey D. Edwards (Pres. & CEO); Simon Watson (Sec. & CFO);
|
| |
|
Auditor:
James Stafford Chartered Accountants
|
| |
|
Securities:
Common Stock-Symbol MLPH.OB; OTC BB;
111,553,740 common shares outstanding as of September 27, 2007.
|
| |
| |
| |
| return to main page |
